reports
- Guy Sips
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Hilde Van Boxstael
- Mathijs Geerts Danau
- Wim Lewi
- Mathijs Geerts Danau
Sequana Medical New DSR patent improves value of program
Sequana announces granting of a key additional methods and formulation patent for DSR. This patent increases durability and expands protection of Sequana's DSR IP, thereby improving its value. We note that the patent provides additional time for Sequana to secure dedicated financing to advance DSR toward the randomized controlled portion of the MOJAVE clinical study. We reiterate our BUY rating.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Wim Hoste
- Wim Lewi
- Mathijs Geerts Danau
Sequana Medical Announces first US sale of the alfapump
Sequana reported the first US commercial alfapump implant at Mount Sinai Hospital in New York. This important milestone shows the demand for the alfapump in the US. We adjust our TP from € 2.8 to € 2.7 to reflect the new share count and reiterate our BUY rating.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Mathijs Geerts Danau
- Thibault Leneeuw
- Wim Lewi
- Wim Hoste
Belysse Weak 3Q revenue performance
3Q25 revenue dropped by 10.9%, which was below our forecast of about -1%. Both Europe and US saw revenue decline by double digits, although the drop in the US was only mid single digits when excluding FX effects. 3Q25 adjusted EBITDA was not disclosed but was said to be down y/y, which is not surprising given the weak top line momentum. We have lowered our FY25 and FY26 adjusted EBITDA forecasts by respectively 10% and 8%. Despite the disappointing top line momentum, valuation continues to look ...
- Guy Sips
- Jacob Mekhael
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Livio Luyten
- Mathijs Geerts Danau
- Michiel Declercq
- Thibault Leneeuw
- Wim Hoste
- Jacob Mekhael
- Mathijs Geerts Danau
Life Sciences Conference 25 Sep 2025
KBC Securities will host its annual life sciences conference on 25 September in Brussels. The event will include 14 exciting companies, both public and private, from the BeNeLux ecosystem and beyond. In this conference note, we provide an overview of the attending companies, as well as an outlook on KBC Securities' life sciences broader coverage.
- Wim Hoste
Belysse 1H adjusted EBITDA down on Europe but market bottoming out?
1H adjusted EBITDA dropped by c. 20% which was below our expectations. Belysse. The decline is entirely due to Europe, as the US business held up very well and even increased adjusted EBITDA y/y, on stable volumes and higher unitary margins. After the weaker than expected 1H performance, we have lowered our FY25/26 adjusted EBITDA forecasts by c. 9%. Nevertheless, European volumes appear to be bottoming out and any volume rebound might have a significant positive effect on margins. Valuation con...
- Jacob Mekhael
- Lynn Hautekeete
- Mathijs Geerts Danau
- Michiel Declercq
- Thomas Couvreur
- Jacob Mekhael
Sequana Medical Publishes alfapump case report in journal, US launch o...
Sequana announced the publication of a case report of a patient in the POSEIDON study that underwent a successful robotic hernia repair following control of their ascites with the alfapump. Looking ahead, the US commercial launch remains on track for this quarter. Should the company demonstrate initial commercial traction during the soft launch phase, this could trigger additional investor interest to fund the company into the broader launch, which is expected in 2Q26. We reiterate our € 5 TP an...
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Livio Luyten
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Sequana Medical Extends runway into 1Q26 with additional € 6.3m conver...
Sequana announced that SFPIM and other existing shareholders have invested a further € 6.3m in the 2025 convertible loan announced on 18 March 2025. Sequana's cash runway has now been extended into 1Q26 (previously YE25), which will provide Sequana with more breathing room to demonstrate initial commercial traction during the soft launch phase of the alfapump's US commercialisation in 3Q25. This could trigger additional investor interest to fund the company into the broader launch, which is expe...
- Jacob Mekhael
- Thomas Couvreur
- Wim Hoste
Belysse 1Q25 revenue -4.3%, reflecting weaker performance in Europe
1Q revenue dropped by 4.3%, reflecting weaker demand in Europe against a tough comparable. 1Q adjusted EBITDA declined, due to a lower performance in Europe despite growth in the US. After the weaker than expected 1Q performance, we have lowered our FY25/26 adjusted EBITDA forecasts by c. 5%. Valuation continues to look attractive and prompts us to reiterate our Accumulate rating and € 1.6 target price.
- Guy Sips
- Hilde Van Boxstael
- Jacob Mekhael
- Kristof Samoy
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
Sequana Medical CMS proposes NTAP top up payment for the alfapump
Sequana announced that the Centers for Medicare and Medicaid Services (CMS) recommends that alfapump system cases be eligible for incremental payment via a new technology add-on payment (NTAP). This proposal could bring an NTAP top-up payment of up to $ 19,500 on top of the existing DRG payments, boosting the device's reimbursement position, and could make the alfapump procedure profitable for hospitals, which is likely to help drive adoption. With center training due to be completed by the end ...
- Jacob Mekhael
Sequana Medical FIRST LOOK: Additional funding extends runway to YE25
Sequana announced that it has secured additional financing including a €4m convertible, and a facility agreement with GEM up to €20m, as well as amending the terms of the Kreos and PMV loans. The new cash provides funding to YE25, and gives the company breathing room to progress towards US commercialisation of the alfapump expected in 3Q25. We plan to incorporate this new financing in a future model update. BUY reiterated.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.